EQS-News: Sartorius marks positive start to 2...

Sartorius AG (AIM:0NIR) has reported a positive start to 2026, with group sales revenue increasing by 7.5% in constant currencies to €899 million. This growth was primarily driven by strong recurring business in both its Bioprocess Solutions and Lab Products & Services divisions. The Bioprocess Solutions Division saw an 8.1% increase in sales revenue, while the Lab Products & Services Division returned to growth with a 4.9% rise. The company also maintained a resilient underlying EBITDA margin of 29.7%. Sartorius confirmed its full-year guidance for 2026, expecting sales revenue growth between 5% and 9% and an underlying EBITDA margin slightly above 30%.

When comparing this announcement to Sartorius's previous disclosures, it is evident that the company is on track with its growth trajectory. The reported sales revenue of €899 million aligns with the company's expectations, as indicated in prior communications regarding its performance in 2026. The growth in both divisions, particularly the Bioprocess Solutions Division, which accounts for a significant portion of total sales, reflects the company's strategic focus on recurring consumables and services. However, it is important to note that while the Lab Products & Services Division has returned to growth, it had previously faced challenges, and the current growth rate is against a lower prior-year comparison base.

Financially, Sartorius appears to be in a stable position. The underlying EBITDA of €267 million represents a slight increase of 1.6% compared to the previous year, indicating that profitability remains resilient despite external pressures such as tariffs and macroeconomic uncertainties. The equity ratio stands at a robust 39.4%, and the net debt to underlying EBITDA ratio has been slightly reduced to 3.53, suggesting that the company is managing its leverage effectively. Sartorius's investments in research and production infrastructure, amounting to €78 million in the first quarter, reflect its commitment to future growth, although these investments have contributed to a slight decrease in underlying net profit.

In terms of valuation, Sartorius's performance can be compared to its peers in the life sciences sector. Companies such as Thermo Fisher Scientific (NYSE:TMO) and Merck KGaA (XETRA:MRK) provide a relevant benchmark. Thermo Fisher, for instance, has a market cap significantly larger than Sartorius, but it also operates in a similar space with a focus on bioprocessing and laboratory products. Merck KGaA, while also larger, has shown consistent growth in its life sciences division, indicating that Sartorius's growth trajectory is in line with broader industry trends. However, Sartorius's current EBITDA margin of 29.7% is competitive, especially considering the pressures it faces from tariffs and product mix effects.

One notable positive from this announcement is the successful integration of MATTEK, the microtissue specialist acquired in July 2025, which contributed 0.5 percentage points to sales revenue growth. This acquisition reflects Sartorius's strategy to enhance its product portfolio and address the growing demand for innovative solutions in biopharmaceutical manufacturing. The introduction of the Eveo Cell Therapy Platform and a new genetically engineered CHO host cell line further demonstrates Sartorius's commitment to innovation and meeting customer needs in a rapidly evolving market.

Looking ahead, Sartorius has confirmed its full-year guidance for 2026, which is a positive signal for investors. The expectation of continued sales revenue growth and a stable EBITDA margin suggests that the company is well-positioned to navigate the challenges of the current economic climate. The next expected catalyst will likely be the release of further quarterly results, which will provide additional insights into the company's performance and its ability to meet the outlined guidance.

In conclusion, Sartorius AG's announcement of a positive start to 2026 is supported by solid financial performance and strategic growth initiatives. The company's ability to maintain a resilient profit margin while navigating external challenges is commendable. Overall, this announcement can be classified as significant, as it not only confirms the company's growth trajectory but also highlights its strategic focus on innovation and recurring business. The headline sentiment is warranted by the full picture, reflecting Sartorius's strong position in the life sciences sector.

Key insights

• ●Sartorius's sales revenue grew by 7.5%, confirming its growth trajectory.
• ●The integration of MATTEK contributed positively to revenue growth.
• ●The company maintains a resilient EBITDA margin despite external pressures.

Disagree with this article?